Yet more uncertainty for pharma over SPCs in the EU
This article was originally published in SRA
As an English High Court judge refers yet another set of questions on the Supplementary Protection Certificate Regulation to the Court of Justice of the EU, Katie McConnell and Emma Fulton discuss the issues involved.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.